Course: Evolving Treatment Paradigms in HR+/HER2- Early Breast Cancer: Advancing Equitable Care in Rural and Underserved Communities
CME Credits: 0.00
Released: 2024-12-13
Hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2-) breast cancer accounts for up to 70% of all breast cancer cases. In recent years, therapies such as CDK4/6 inhibitors, PARP inhibitors, and novel endocrine therapies have been shown to improve outcomes in these patients. However, women in rural and underserved communities often face significant barriers such as oncologist shortages and geographic barriers, leading to disparities in care. This CME/CE activity will cover current and emerging treatment options for HR+/HER2- early breast cancer and the latest guidance on how to integrate biomarker and genetic testing into clinical practice. Expert faculty will also share collaborative strategies to improve early breast cancer care and management in rural and underserved settings. This enduring activity is a recorded session from Oncology Congress that took place on September 28, 2024.
Upon completion of this activity, participants should be better able to:
View Full Course